截至9月30日，诚达药业股东户数1.27万，较上期减少8.58%；人均流通股8577股，较上期增加36.16%。 2025年1月-9月，诚达药业实现营业收入2.85亿元，同比增长16.95%；归母净利润1677.33万元，同比减 少58.47%。 分红方面，诚达药业A股上市后累计派现1.33亿元。近三年，累计派现8961.79万元。 责任编辑：小浪快报 11月6日，诚达药业涨0.93%，成交额9517.68万元。两融数据显示，当日诚达药业获融资买入额1462.49 万元，融资偿还1534.27万元，融资净买入-71.78万元。截至11月6日，诚达药业融资融券余额合计2.47 亿元。 融资方面，诚达药业当日融资买入1462.49万元。当前融资余额2.47亿元，占流通市值的5.09%，融资余 额超过近一年90%分位水平，处于高位。 融券方面，诚达药业11月6日融券偿还0.00股，融券卖出0.00股，按当日收盘价计算，卖出金额0.00元； 融券余量0.00股，融券余额0.00元，低于近一年50%分位水平，处于较低位。 资料显示，诚达药业股份有限公司位于浙江省嘉兴市嘉善县惠民街道黄河路36号，成立日期1999年3月 ...

Core Viewpoint - Chengda Pharmaceutical is a leading domestic pharmaceutical company focusing on key pharmaceutical intermediates CDMO services and L-carnitine series products, with strong R&D capabilities [1] Group 1: Business Performance - In Q3 2025, Chengda Pharmaceutical reported revenue of 285 million yuan, ranking 26th out of 29 in the industry, significantly lower than the top company WuXi AppTec at 32.857 billion yuan and second-ranked Kanglong Chemical at 10.086 billion yuan [2] - The net profit for Q3 2025 was 16.7931 million yuan, ranking 22nd out of 29, with a notable gap compared to WuXi AppTec's 12.206 billion yuan and Tigermed's 1.092 billion yuan [2] Group 2: Financial Ratios - Chengda Pharmaceutical's debt-to-asset ratio in Q3 2025 was 9.98%, up from 6.78% year-on-year, significantly lower than the industry average of 22.79%, indicating strong solvency [3] - The gross profit margin for Q3 2025 was 45.39%, an increase from 43.54% year-on-year, surpassing the industry average of 37.70%, reflecting strong profitability [3] Group 3: Executive Compensation - The chairman, Ge Jianli, received a salary of 602,700 yuan in 2024, a decrease of 374,200 yuan from 2023 [4] - The general manager, Lu Gang, earned 668,800 yuan in 2024, down 223,900 yuan from the previous year [4] Group 4: Shareholder Information - As of September 30, 2025, the number of A-share shareholders decreased by 8.58% to 12,700, while the average number of circulating A-shares held per account increased by 36.16% to 8,577.86 [5]

Core Viewpoint - Chengda Pharmaceutical's stock performance shows a slight increase, with significant financing activity indicating investor interest despite a decline in net profit year-over-year [1][2]. Financing Activity - On October 28, Chengda Pharmaceutical's stock rose by 0.46%, with a trading volume of 103 million yuan. The financing buy-in amounted to 10.23 million yuan, while financing repayment was 8.51 million yuan, resulting in a net financing buy-in of 1.72 million yuan [1]. - As of October 28, the total financing and securities lending balance for Chengda Pharmaceutical was 254 million yuan, representing 4.99% of its market capitalization. This financing balance is above the 90th percentile of the past year, indicating a high level of investor engagement [1]. - In terms of securities lending, there were no shares repaid or sold on October 28, with a total securities lending balance of 0, which is below the 50th percentile of the past year, indicating a low level of short selling activity [1]. Financial Performance - For the period from January to September 2025, Chengda Pharmaceutical reported a revenue of 285 million yuan, reflecting a year-over-year growth of 16.95%. However, the net profit attributable to shareholders decreased by 58.47% to 16.77 million yuan [2]. - As of September 30, the number of shareholders for Chengda Pharmaceutical was 12,700, a decrease of 8.58% from the previous period. The average number of circulating shares per shareholder increased by 36.16% to 8,577 shares [2]. Dividend Distribution - Since its A-share listing, Chengda Pharmaceutical has distributed a total of 133 million yuan in dividends, with 89.62 million yuan distributed over the past three years [3].